Author
@OzmosiHealth OzmosiHealth
Real-time biotech catalyst and regulatory event feed across hundreds of clinical-stage names
Publishes a structured, link-backed stream of biotech/pharma
trader score
·
hit rate
·
mean α
·
signals 14d
99
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved +1.1% since posting (mean over 24 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | CAPR | @OzmosiHealth | -0.50 | Reports an FDA review extension amid a securities class action and lead-plaintiff deadline. | · | tweet ↗ |
| 2026-08-28 | CRSP | @OzmosiHealth | +0.55 | Phase 1a data show deep, durable editing and triglyceride and LDL reductions. | — | tweet ↗ |
| 2026-08-28 | 4568 | @OzmosiHealth | +0.25 | Daiichi Sankyo presents new real-world bempedoic-acid effectiveness data. | · | tweet ↗ |
| 2026-08-28 | RHHBY | @OzmosiHealth | +0.45 | Roche reports sustained two-year Vabysmo results in difficult-to-treat nAMD. | — | tweet ↗ |
| 2026-08-28 | QNRX | @OzmosiHealth | +0.55 | Quoin reports positive interim Phase 2/3 data for QRX003. | · | tweet ↗ |
| 2026-08-28 | LLY | @OzmosiHealth | +0.50 | FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes. | — | tweet ↗ |
| 2026-08-28 | OSE | @OzmosiHealth | +0.00 | Announces a September 2, 2026 KOL webcast concerning lusvertikimab. | · | tweet ↗ |
| 2026-08-27 | ACET | @OzmosiHealth | +0.50 | FDA cleared Adicet Bio's IND application for ADI-212. | · | tweet ↗ |
| 2026-08-27 | OTLK | @OzmosiHealth | +0.10 | Outlook Therapeutics appointed Kevin Lundquist as CFO. | +0.6% | tweet ↗ |
| 2026-08-27 | ROIV | @OzmosiHealth | +0.50 | FDA approved LISRAYA for adults with dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | ROIV | @OzmosiHealth | +0.50 | FDA approved LISRAYA for adults with dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | ROIV | @OzmosiHealth | +0.50 | Priovant announced FDA approval of LISRAYA for adult dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | ROIV | @OzmosiHealth | +0.50 | Priovant announced FDA approval of LISRAYA for adult dermatomyositis. | · | tweet ↗ |
| 2026-08-27 | DTIL | @OzmosiHealth | +0.05 | Reports presentation of updated OTC-HOPE clinical data at SSIEM 2026. | · | tweet ↗ |
| 2026-08-27 | ABBV | @OzmosiHealth | +0.15 | AbbVie submitted an EMA regulatory application for SKYRIZI induction therapy. | -1.0% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.